Research Article
Effectiveness and Safety of PD-1 Inhibitors’ Treatment for Patients with Non-Small-Cell Lung Cancer in China: A Real-World Study
Table 5
Treatment-related adverse events.
| | Adverse reactions | Total (N, %) | Grade 1-2 (N, %) | Grade ≥3 (N, %) |
| | Any AEs | 140 (83.83) | 99 (59.28) | 41 (24.55) | | Anemia | 122 (73.05) | 102 (61.08) | 20 (11.98) | | White blood cell count decreased | 42 (25.15) | 32 (19.16) | 10 (5.99) | | Neutrophil count decreased | 32 (19.16) | 22 (13.17) | 10 (5.99) | | Platelet count decreased | 19 (11.38) | 13 (7.78) | 6 (3.59) | | Creatinine elevation | 33 (19.76) | 33 (19.76) | 0 (0.00) | | Alanine aminotransferase increased | 37 (22.16) | 34 (20.36) | 3 (1.80) | | Aspartate aminotransferase increased | 14 (8.38) | 13 (7.78) | 1 (0.60) | | Rash | 6 (3.59) | 6 (3.59) | 0 (0.00) | | Pruritus | 7 (4.19) | 7 (4.19) | 0 (0.00) | | Pyrexia | 11 (6.59) | 11 (6.59) | 0 (0.00) | | Hypothyroidism | 3 (1.80) | 3 (1.80) | 0 (0.00) | | Hyperthyroidism | 5 (2.99) | 5 (2.99) | 0 (0.00) | | Any irAEs | 19 (11.38) | 11 (6.59) | 8 (4.79) | | RCCEP | 10 (5.99) | 5 (2.99) | 5 (2.99) | | ICI-induced pneumonitis | 6 (3.59) | 4 (2.40) | 2 (1.20) | | ICI-induced immune mediated hepatitis | 1 (0.60) | 1 (0.60) | 0 (0.00) | | ICI-associated cardiotoxicity | 2 (1.20) | 2 (1.20) | 0 (0.00) | | ICI-induced gastrointestinal toxicity | 1 (0.60) | 0 (0.00) | 1 (0.60) | | ICI-induced endocrinopathy | 1 (0.60) | 1 (0.60) | 0 (0.00) | | ICI-induced myositis | 1 (0.60) | 1 (0.60) | 0 (0.00) |
|
|
